top of page
Syringe

HUMAN PRODUCTS

IQ-IDM development activity for safe and effective interventions for infectious disease in humans

IQ-181

Pre-clinical phase

IQ-174

Influenza

Discovery phase

More information will follow soon

More information will follow soon

IQ-160

Discovery phase

More information will follow soon

IQ-241

Discovery phase

More information will follow soon

RSV-virus,-Respiratory-syncytial-virus,-human-orthopneumovirus,-is-a-common,-contagious-ai

Human RSV

  • Virtually all children get an RSV infection by the time they are 2 years old. Most of the time RSV will cause a mild, cold-like illness, but it can also cause severe illness such as

    • Bronchiolitis (inflammation of the small airways in the lung)

    • Pneumonia (infection of the lungs)

  • Two to three out of every 100 infants with RSV infection may need to be hospitalized. Those who are hospitalized may require oxygen, IV fluids (if they aren’t eating and drinking), and mechanical ventilation (a machine to help with breathing). 

  • Each year in the United States, an estimated 58,000-80,000 children younger than 5 years are hospitalized due to RSV infection. (CDC)

Rabies

  • The rabies virus infects the central nervous system. If a person does not receive the appropriate medical care after a potential rabies exposure, the virus can cause disease in the brain, ultimately resulting in death.

  • Each year, rabies causes approximately 59,000 deaths worldwide. (CDC)

Rabies-Virus-3D-Illustration-1281334790_1258x839.jpeg
Dengue-virus-which-causes-yellow-fever-623941678_3000x2000.jpeg

Dengue

  • Despite the availability of Dengue vaccines, the number of Dengue cases world-wide including the United states and Europe have significantly increased. About half of the world's population is now at risk of dengue with an estimated 100–400 million infections occurring each year (WHO Dengue fact sheet April 2024).

  • The potential distribution of the vector (the yellow Fever Mosquito or Aedis Aegypti) is predicted to increase 10–30% globally by the end of the century leading to the majority of Europe and the US vulnerable to Dengue epidemics.

  • While most pharmaceutical companies focus their development efforts on prophylactics for travellers to endemic areas,  the development of therapeutic options for people living in endemic countries (96 million clinical manifestations per year) has been neglected and is sorely lagging.

  • IQ-IDM has identified small molecules for the treatment of Dengue haemorrhagic fever that can be manufactured at low cost. 

bottom of page